Interpretation of social organization standard of Diagnosis Specification of Intraocular Tuberculosis

doi:10.19982/j.issn.1000-6621.20240572

Chinese Journal of Antituberculosis ›› 2025, Vol. 47 ›› Issue (3): 258-261.doi: 10.19982/j.issn.1000-6621.20240572

• Interpretation of Standards • Previous Articles Next Articles

Interpretation of social organization standard of Diagnosis Specification of Intraocular Tuberculosis

Duan Hongfei¹, Tao Yong²()

¹Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
²Department of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China

Received:2024-12-17 Online:2025-03-10 Published:2025-02-27
Contact: Tao Yong, Email: taoyong@mail.ccmu.edu.cn
Supported by:
Beijing High-Level Public Health Talent Program(Discipline Leader-03-008);National Natural Science Foundation of China(82471081);Beijing Hospitals Authority’s Ascent(DFL20220301);Capital Health Development Research Special Project(2022-2-2035);Excellent Young Talent Innovation Project from the Chinese Institutes for Medical Research(CX23YQA02)

Abstract

Abstract:

On October 17, 2024, the social organization standard Diagnosis Specification of Intraocular Tuberculosis (T/CHATA 045—2024) was officially released and implemented on the same day. This article interprets the core points of the standard, aiming to help medical personnel at all levels of healthcare institutions across the country grasp the key points of intraocular tuberculosis diagnosis, improve the standardization of diagnosis, reduce misdiagnosis and missed diagnosis, and regulate diagnosis.

Key words: Tuberculosis, ocular, Diagnosis, differential, Benchmarking, Comment

CLC Number:

R52
R771

Duan Hongfei, Tao Yong. Interpretation of social organization standard of Diagnosis Specification of Intraocular Tuberculosis[J]. Chinese Journal of Antituberculosis, 2025, 47(3): 258-261. doi: 10.19982/j.issn.1000-6621.20240572

References 8

[1]	World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization, 2024.
[2]	Agrawal R, Gunasekeran DV, Grant R, et al. Clinical Features and Outcomes of Patients With Tubercular Uveitis Treated With Antitubercular Therapy in the Collaborative Ocular Tuberculosis Study (COTS)-1. JAMA Ophthalmol, 2017, 135(12): 1318-1327. doi:10.1001/jamaophthalmol.2017.4485. pmid: 29075752
[3]	Dalvin LA, Smith WM. Intraocular manifestations of Mycobacterium tuberculosis: A review of the literature. J Clin Tuberc Other Mycobact Dis, 2017, 7: 13-21. doi:10.1016/j.jctube.2017.01.003.
[4]	Gupta A, Sharma A, Bansal R, et al. Classification of intraocular tuberculosis. Ocul Immunol Inflamm, 2015, 23(1): 7-13. doi:10.3109/09273948.2014.967358. pmid: 25314361
[5]	Xie J, Qu Y, Qian Z, et al. Clinical manifestation and long-term follow-up of presumed ocular tuberculosis in China. J Clin Tuberc Other Mycobact Dis, 2023, 34: 100413. doi:10.1016/j.jctube.2023.100413.
[6]	Agrawal R, Betzler BK, Testi I, et al. The Collaborative Ocular Tuberculosis Study (COTS) -1: A Multinational Review of 447 Patients with Tubercular Intermediate Uveitis and Panuveitis. Ocul Immunol Inflamm, 2020, 28(sup1): 27-37. doi:10.1080/09273948.2020.1808226.
[7]	Agrawal R, Testi I, Bodaghi B, et al. Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitis-Report 2: Guidelines for Initiating Antitubercular Therapy in Anterior Uveitis, Intermediate Uveitis, Panuveitis, and Retinal Vasculitis. Ophthalmology, 2021, 128(2): 277-287. doi:10.1016/j.ophtha.2020.06.052. pmid: 32603726
[8]	Jiang T, Zhang X, Zhou M, et al. Prognosis of Ocular Tuberculosis Following Long-Term Antitubercular Therapy. J Ocul Pharmacol Ther, 2021, 37(4): 241-247. doi:10.1089/jop.2020.0100. pmid: 33524301

[1]	Zhao Yanli, Che Nanying. Interpretation of social organization standard of Specification for Pathological Diagnosis of Tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(4): 371-374.
[2]	AN Hui-ru, WU Xue-qiong. Interpretation of immunoadjuvant therapy in Expert consensus on immune function assessment and immunotherapy in patients with active tuberculosis (2021 Edition) [J]. Chinese Journal of Antituberculosis, 2022, 44(6): 539-543.
[3]	LI Ren-zhong, RUAN Yun-zhou, LI Yu-hong. Interpretation of the new definition of extensive drug-resistant tuberculosis defined by World Health Organization [J]. Chinese Journal of Antituberculosis, 2021, 43(6): 539-541.
[4]	LIU Er-yong, LI Yu-hong, ZHOU Lin, ZHAO Yan-lin. Making panoramic plan:extra-pulmonary tuberculosis needs to be integrated into the national tuberculosis program [J]. Chinese Journal of Antituberculosis, 2021, 43(5): 428-431.
[5]	DENG Guo-fang. Interpretation of Expert consensus on treatment and management of tuberculosis-diabetes mellitus comorbidity [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 318-321.
[6]	FENG Ying, REN Fei. Interpretation of Clinical Guidelines for the management of Rifampicin-resistant Tuberculosis in South Africa (2019) and its comparison with Guidelines for Drug-resistant Tuberculosis Chemotherapy in China (2019) [J]. Chinese Journal of Antituberculosis, 2021, 43(3): 295-298.
[7]	HE Xiao-xin, LI Bo, ZHOU Lin. Interpretation of Four-month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(12): 1243-1247.
[8]	YANG Chun-long, ZHOU Lin, CHEN Ming-ting. Interpretation of the Diagnosis process for etiology negative pulmonary tuberculosis (T/CHATA 008—2020) [J]. Chinese Journal of Antituberculosis, 2021, 43(11): 1116-1119.
[9]	JIN Hong-jian. The construction of tuberculosis prevention and control service system at county level in China needs to be strengthened urgently —— Comments and suggestions of an old tuberculosis control and prevention worker [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 896-902.
[10]	ZHANG Can-you, XIA Hui, CHENG Jun. Testing and reporting requirements for Class Ⅱ biosafety cabinet in tuberculosis laboratory [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 903-909.
[11]	CHENG Jun. Interpretation of the Specification of tuberculosis examination for student entrance physical examination [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 987-989.
[12]	SHEN Xin, XIAO Xiao, BAI Li-qiong, PAN Qi-chao. Interpretation of the Guidelines on management of close contacts of active pulmonary tuberculosis cases in schools [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 990-991.
[13]	LI Tao, DU Xin, CHEN Wei, HUANG Fei, ZHAO Yan-lin, ZHANG Hui. Review and prospect of tuberculosis management information surveillance and monitoring in China [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 657-661.
[14]	SHEN Xin, SHA Wei, LIU Jian-jun. Impact of coronavirus disease 2019 (COVID-19) on tuberculosis control and countermeasures in China [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 544-548.
[15]	SONG Qi-sheng, LU Xi-wei. Progress and prospect of positron emission computed tomography applied in clinical research of pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 621-625.

Interpretation of social organization standard of Diagnosis Specification of Intraocular Tuberculosis

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 8

Related Articles 15

Recommended Articles

Metrics

Comments